To our knowledge, only one pilot study was published showing that intraocular fasudil, a specific ROCK inhibitor, combined with intravitreal bevacizumab (anti-VEGF) was beneficial for patients with macular edema resistant to anti-VEGF alone26. The gene discussed is VEGFA; the disease is macular retinal edema.